# TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet

> **NCT00752310** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 23 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Darunavir

## Key facts

- **NCT ID:** NCT00752310
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2011-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752310, "TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00752310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*